Publications by authors named "Antoine Tshomba Oloma"
Article Synopsis
- A clinical trial was conducted in the Democratic Republic of Congo to evaluate the safety and efficacy of four experimental therapies for Ebola virus disease (EVD) during an outbreak that started in August 2018.
- 681 patients were randomly assigned to receive either ZMapp, remdesivir, MAb114, or REGN-EB3, with the primary endpoint being mortality at 28 days.
- Results indicated MAb114 and REGN-EB3 significantly reduced mortality compared to ZMapp and remdesivir, leading to a recommendation to continue only with these two therapies for the remainder of the trial.
Data collected during the 2012 Ebola virus disease (EVD) epidemic in the Democratic Republic of the Congo were analysed for clinical signs, symptoms and case fatality of EVD caused by Bundibugyo virus (BDBV), establishment of differential diagnoses, description of medical treatment and evaluation of the quality of clinical documentation. In a quantitative observational prospective study, global epidemiological data from 52 patients (34 patients within the community, 18 patients treated in the Ebola Treatment Centre) were entered anonymously into a database, subsequently matched and analysed. Relevant findings include an over-representation of females among community EVD cases (85.
View Article and Find Full Text PDF